Our data indicated that 7.0 weeks of HFCD feeding represents a suitable time point to study both atherosclerosis and NASH as concomitant diseases, and this protocol was selected to evaluate the role of IDO1 in disease. The gene discussed is IDO1; the disease is metabolic dysfunction-associated steatohepatitis.